Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy
plus stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy
to the locoregional primary tumour, in patients with histologically-confirmed synchronous
oligo-metastatic non-small cell lung cancer (NSCLC).